Human Reproduction Update, Vol.3, No.4 pp.359-365, 1997
© European Society of Human Reproduction and Embryology 1997; all rights reserved
Modern use of clomiphene citrate in induction of ovulation
Department of Obstetrics and Gynaecology, Imperial College School of Medicine at St. Mary's, London W2 1PG, UK 0 Corresponding author Tel: +44 (0)171 724 2306; Fax: +44 (0)171 886 6037
Abstract
Clomiphene citrate is the treatment of first choice in the management of infertility in normally oestrogenized, anovulatory women (WH0 group II). The majority of women with 'pure' anovulatory infertility respond to treatment with clomiphene citrate. The rates of pregnancy and miscarriage are close to those expected in a normal fertile population. Basal hormone concentrations do not predict outcome. An increased body mass index is the only factor which is consistently associated with a decreased response to clomiphene citrate; it follows therefore, that weight reduction should be an important part of therapy in anovulatory women. According to our data, only an increased luteinizing hormone value immediately post clomiphene citrate predicted an adverse pregnancy outcome in women who conceived. Clomiphene citrate, along with other ovulation induction therapies, can cause multiple follicular development, with a risk of ovarian hyperstimulation and multiple pregnancy. Ultrasound monitoring of treatment is important in order to choose the appropriate dose of clomiphene citrate in subsequent cycles and to minimize the risks of hyperstimulation and multiple pregnancy. When couples with other factors contributing to subfertility are excluded, the cumulative conception rate continues to rise after 6 months of treatment with clomiphene citrate, reaches a plateau by treatment cycle 12 and approaches that of the normal population. It has been reported that prolonged use of clomiphene citrate may be associated with an increased risk of a borderline or invasive ovarian tumour. Taking into consideration these observations, we recommend that anovulatory women responsive to clomiphene citrate should be treated for at least 6 cycles before considering more complex or invasive methods of ovulation induction, and that treatment should probably be limited to a maximum of 12 cycles.
Keywords: clomiphene/induction of ovulation/LH/outcome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.A. Amer, T.C. Li, M. Metwally, M. Emarh, and W.L. Ledger Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome Hum. Reprod., January 1, 2009; 24(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Requena, J. Herrero, J. Landeras, E. Navarro, J. L. Neyro, C. Salvador, R. Tur, J. Callejo, M. A. Checa, M. Farre, et al. Use of letrozole in assisted reproduction: a systematic review and meta-analysis Hum. Reprod. Update, November 1, 2008; 14(6): 571 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koivunen, A. Pouta, S. Franks, H. Martikainen, U. Sovio, A-L. Hartikainen, M.I. McCarthy, A. Ruokonen, A. Bloigu, M-R. Jarvelin, et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study Hum. Reprod., September 1, 2008; 23(9): 2134 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Balen and A. J Rutherford Managing anovulatory infertility and polycystic ovary syndrome BMJ, September 29, 2007; 335(7621): 663 - 666. [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, T. Russo, F. Orio Jr, A. Falbo, F. Manguso, A. Sammartino, A. Tolino, A. Colao, E. Carmina, and F. Zullo Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study Hum. Reprod., November 1, 2006; 21(11): 2823 - 2829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Elnashar, E. Abdelmageed, M. Fayed, and M. Sharaf Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study Hum. Reprod., July 1, 2006; 21(7): 1805 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Franks Diagnosis of Polycystic Ovarian Syndrome: In Defense of the Rotterdam Criteria J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 786 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Homburg Clomiphene citrate--end of an era? a mini-review Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, F. Orio Jr., A. Falbo, F. Manguso, T. Russo, T. Cascella, A. Tolino, E. Carmina, A. Colao, and F. Zullo Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4068 - 4074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kashyap, G. A. Wells, and Z. Rosenwaks Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome Hum. Reprod., November 1, 2004; 19(11): 2474 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.A.K. Amer, T.C. Li, and W.L. Ledger Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success Hum. Reprod., August 1, 2004; 19(8): 1719 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.C. Eijkemans, B. Imani, A. G.M.G.J. Mulders, J.D. F. Habbema, and B. C.J.M. Fauser High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2) Hum. Reprod., November 1, 2003; 18(11): 2357 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Lord, I. H K Flight, and R. J Norman Metformin in polycystic ovary syndrome: systematic review and meta-analysis BMJ, October 25, 2003; 327(7421): 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.F.M. Mitwally and R.F. Casper Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility Hum. Reprod., August 1, 2003; 18(8): 1588 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Tackling polycystic ovary syndrome DTB, January 1, 2001; 39(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. louffe Jr. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice Reproductive Sciences, January 1, 2000; 7(1_suppl): S38 - S46. [Abstract] [PDF]
|
|
|
|
|
|
B. Imani, M. J. C. Eijkemans, E. R. te Velde, J. D. F. Habbema, and B. C. J. M. Fauser Predictors of Chances to Conceive in Ovulatory Patients during Clomiphene Citrate Induction of Ovulation in Normogonadotropic Oligoamenorrheic Infertility J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1617 - 1622. [Abstract] [Full Text]
|
|
|
|
|
|
B. Imani, M. J. C. Eijkemans, E. R. te Velde, J. D. F. Habbema, and B. C. J. M. Fauser Predictors of Patients Remaining Anovulatory during Clomiphene Citrate Induction of Ovulation in Normogonadotropic Oligoamenorrheic Infertility J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2361 - 2365. [Abstract] [Full Text]
|
|